活动依赖性神经保护蛋白 (ADNP) 的降低有助于补充阿尔茨海默病中的基因升高
Yong Ren1,2, Komal Saleem2, Prachetas Jai Patel2
1VA Western New York Healthcare System, Medical Research, Buffalo, NY, USA.
Journal of Alzheimer's disease : JAD
|March 12, 2026
概括
阿尔茨海默病 (AD) 大脑中活动依赖神经保护蛋白 (ADNP) 的减少可能导致基因失调. 这种表观遗传变化提升了补充基因,导致AD患者的认知能力下降.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 基因失调将阿尔茨海默病 (AD) 病理与认知障碍联系起来.
- 补充基因在阿兹海默症患者的前额叶皮质 (PFC) 中被上调.
- 补充基因调节组织平衡和免疫监测.
研究的目的:
- 确定AD中补充基因升高的关键转录调节器.
- 研究ADNP (活动依赖神经保护蛋白) 在AD病变发生过程中的作用.
- 探索阿尔茨海默病中基因失调背后的表观遗传机制.
主要方法:
- 对人类死后PFC进行了转录基因和表观基因分析.
- 使用了分子,生化和免疫细胞化学分析.
- 在小鼠模型中进行了体内基因操纵和iPSC衍生的神经元培养.
主要成果:
- 染色体调节剂ADNP被确定为AD中补充基因的顶级转录因子.
- 在死后的AD PFC和5xFAD小鼠模型中,ADNP和HP1γ (异染色蛋白1蛋白) 水平降低.
- 在小鼠中减少ADNP表达导致补充基因水平增加,模仿AD条件.
- 来自患者的神经元培养物显示出星球细胞激活,ADNP/HP1γ减少,补充基因升高.
结论:
- 在AD中ADNP的降低可能会通过中断的转录抑制导致染色质失调.
- 这种表观遗传机制有助于阿尔茨海默病中补充基因的升高.
- ADNP代表了一种新的上游表观遗传修饰剂,用于AD的基因失调.
关键词:
5xFADAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5xFAD 5XFAD 5XFAD 5XFAD 5XFAD 5XFAD 5XFAD 5XFAD 5XFAD 5XFAD 5XFAD 5XFD在此之前,ADNP是ADNP.阿尔茨海默氏症的疾病是阿尔茨海默氏症.活动依赖的神经保护蛋白质.基因补充 基因补充 基因补充表观遗传学是指表观遗传学.诱导多能干细胞的诱导干细胞.相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Complement System
11.8K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
11.8K
Role of Neurotransmitters in Memory
2.8K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.8K


